The Impact of Clinical Pharmacists Role in Transition of Care From Other Departments to Critical Care Units in Alexandria Main University Hospital.

Transition of care between hospital departments is an important step in patient care. Every patient may need to be transmitted either for case deterioration, improvement or interventions purposes. It includes patient transition from home to hospital, transition from one hospital to another, transition from one department to another in the same hospital, transition from hospital to home. This step has many patient safety risks due to health care teams' miscommunications, shifts handoffs and use of hard copies patients' profiles crowded with papers. So many pharmaceutical and health care organizations mentioned transition of care as one of patient and organizational related quality standards . All health care team members, including clinical pharmacists, have important roles to be played. Clinical pharmacists' services differ according to the setting at which patients are presented in.

They include medication reconciliation, resolution of medications discrepancies and medication related problems, interprofessional collaboration and communication, recommendations to patients and care givers and their engagement in the therapeutic plan and post discharge follow up .

ACCP structured task force recommendations for quality measures and associated metrics according to Avedis Donabedian's model of health care quality. Process metrics involve measuring the proportion of patients receiving transition of care services and calculating the total number of medication discrepancies and medication therapy problems and their distribution, overall and by type. Outcome measures include rates of unplanned 30 days, all cause hospital readmissions, total hospital length of stay, completion rates of first planned follow-up contact within prespecified time intervals as completion of post discharge telephone interview within 72 hours and completion rates of pharmacist-referred visits for preventive medicine or other medication-related concerns.

In this study ,the investigators will focus on clinical pharmacist services within transition in the same hospital from other department to critical care units. the investigatorswill select to measure the most important and applicable outcomes regarding this step of transition.

Study Overview

• Status: Completed
• Conditions: Intensive Care Admission
• Intervention / Treatment: Other: the clinical pharmacists interventions about medication related information during transition of care

• Study Type: Interventional
• Enrollment (Actual): 126
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Alexandria, Egypt
    • Alexandria main university hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:All patients transmitted from any department in the hospital to critical care units.

-

Exclusion Criteria:Patients transmitted from other hospitals.

-

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: patients transmitted from other deprtments to to critical care department

Other: the clinical pharmacists interventions about medication related information during transition of care; the intervention is the clinical pharmacists ' interventions regarding medication related information during transition of care .This includes reviewing medications regimen and treatment plan , documenting patients' drug history, drug related adverse events and detecting medication discrepancies.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the number of prescriptions with accurate medication use information after transition of patients to critical care reviewed by clinical pharmacists compared to that reviewed by critical care physicians.	the number of prescriptions with accurate medication use information (ex: dose, indication, duration, medications should be stopped or added, medications should be monitored) , after transition of patients to critical care reviewed by clinical pharmacists compared to that reviewed by critical care physicians.	2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the total number of detected medication discrepancies and drug related problems and the number in each category	Counting the detected medication discrepancies and drug related problems and categorizing them by type (ex: inaccurate dose, inaccurate route of administration, duplication and unnecessary medications).	2 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
length of patients stay in ICU	length of patients stay in ICU (total number of days)	2 months
mortality rate in patients whom benefited from clinical pharmacists service		2 months

Collaborators and Investigators

• Sponsor: Alexandria University

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2025
• Primary Completion (Actual): April 15, 2025
• Study Completion (Actual): June 15, 2025

Study Registration Dates

• First Submitted: March 25, 2025
• First Submitted That Met QC Criteria: March 25, 2025
• First Posted (Actual): March 31, 2025

Study Record Updates

• Last Update Posted (Estimated): October 2, 2025
• Last Update Submitted That Met QC Criteria: October 1, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 0307050

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No